Neoadjuvant In Situ Immunomodulation (ISIM) regimen comprised of intra-tumoral administration of Flt3L, local radiotherapy, and in situ TLR3/CD40 stimulation, followed by surgical resection in murine metaplastic BC model shows great therapeutic potential for advanced BC (Oba et al., 2021). The gene discussed is CD40; the disease is breast cancer.